Recent investigations have centered on the overlap of GLP-1|GIP|GCGR agonist therapies and dopamine neurotransmission. While GIP stimulators are commonly employed for addressing type 2 diabetes mellitus, their potential impacts on motivation circuits, specifically influenced by DA systems, are receiving significant attention. This report details a